PMV Pharmaceuticals Inc Dossier - Source-backed chat

PMV Pharmaceuticals Inc

PMVPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.23

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.75Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $93.6M

Enterprise Value $81.1M

Shares Outstanding 53.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

PMV Pharmaceuticals is a clinical-stage precision oncology company pioneering the structural correction of mutant p53 proteins. Its lead candidate, rezatapopt (PC14586), targets the p53 Y220C mutation, which is present in approximately 1-1.5% of all solid tumors. Recent Phase 2 PYNNACLE trial data demonstrated a compelling 44% overall response rate (ORR) in platinum-resistant/refractory ovarian cancer, validating the therapeutic concept. With a clear regulatory path toward an NDA submission in Q1 2027 and a cash runway extending into Q2 2027, PMV represents a high-potential, asymmetric biotech investment, albeit with typical clinical-stage development and financing risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$4.00

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.00

Regulatory delays or safety concerns emerge during the final stages of the PYNNACLE trial, pushing the NDA submission past 2027. PMV is forced to raise capital at highly dilutive, depressed valuations, or the drug fails to achieve commercial traction due to competitive entries in the p53 space.

Base CaseCentral scenario

$4.50

PMV successfully completes the Phase 2 PYNNACLE trial and submits its NDA for rezatapopt in ovarian cancer by Q1 2027. The company executes a standard dilutive equity raise or debt facility in late 2026 to extend its cash runway past commercialization, with the stock steadily re-rating toward consensus analyst targets.

Bull CaseUpside scenario

$5.25

Rezatapopt achieves accelerated FDA approval for platinum-resistant/refractory ovarian cancer based on strong Phase 2 PYNNACLE data, followed by rapid tumor-agnostic expansion. PMV secures a lucrative co-development partnership with a major pharmaceutical firm, resolving its cash runway concerns without diluting shareholders.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class selective p53 reactivator with compelling clinical proof-of-concept (44% ORR in ovarian cancer cohort).
FDA Fast Track and Orphan Drug Designations provide significant regulatory advantages and market exclusivity.
Clear near-term regulatory catalyst with an NDA submission planned for Q1 2027.

Key Investment Risks

Pre-revenue clinical-stage biotech with a high cash burn rate and a runway that only extends to Q2 2027, making near-term dilution highly likely.
Single-asset concentration risk, as the company's valuation is heavily tied to the clinical and commercial success of rezatapopt.
Inherent regulatory and clinical trial execution risks, including potential enrollment delays or FDA feedback requiring additional studies.

Thesis Invalidation Triggers

Failure to submit the NDA for rezatapopt in platinum-resistant/refractory ovarian cancer by the first half of 2027.
A significant drop in the overall response rate (ORR) or the emergence of severe, dose-limiting toxicities in the final PYNNACLE trial readout.
Inability to secure additional financing or strategic partnerships before cash reserves fall below three quarters of operating runway.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.